Amgen (NASDAQ:AMGN) has been assigned a $192.00 price target by equities researchers at JPMorgan Chase & Co. in a report issued on Tuesday. The firm currently has a “neutral” rating on the medical research company’s stock. JPMorgan Chase & Co.’s price target points to a potential downside of 2.91% from the stock’s current price.

A number of other equities analysts have also commented on AMGN. Jefferies Financial Group restated a “buy” rating and issued a $220.00 price target on shares of Amgen in a research report on Friday, August 24th. Oppenheimer restated a “buy” rating and issued a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. Wells Fargo & Co restated a “neutral” rating and issued a $197.00 price target on shares of Amgen in a research report on Wednesday, August 29th. Royal Bank of Canada restated a “neutral” rating and issued a $193.00 price target on shares of Amgen in a research report on Monday, September 10th. Finally, Leerink Swann set a $209.00 price target on shares of Amgen and gave the company a “hold” rating in a research report on Monday, September 17th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $205.68.

NASDAQ:AMGN opened at $197.76 on Tuesday. The stock has a market capitalization of $126.02 billion, a price-to-earnings ratio of 15.72, a PEG ratio of 2.05 and a beta of 1.41. Amgen has a 12 month low of $163.31 and a 12 month high of $210.19. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.24. The firm had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $3.27 earnings per share. Research analysts predict that Amgen will post 14.24 earnings per share for the current fiscal year.

In other news, SVP Cynthia M. Patton sold 1,777 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $202.88, for a total transaction of $360,517.76. Following the transaction, the senior vice president now directly owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.19% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in AMGN. FMR LLC raised its stake in shares of Amgen by 4.4% during the third quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock worth $7,425,805,000 after buying an additional 1,505,266 shares during the last quarter. Capital International Investors raised its stake in shares of Amgen by 301.4% during the third quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock worth $2,299,506,000 after buying an additional 8,329,861 shares during the last quarter. Capital World Investors bought a new stake in shares of Amgen during the third quarter worth approximately $952,900,000. LSV Asset Management raised its stake in shares of Amgen by 3.2% during the second quarter. LSV Asset Management now owns 4,157,649 shares of the medical research company’s stock worth $767,460,000 after buying an additional 128,865 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Amgen by 8.2% during the third quarter. Renaissance Technologies LLC now owns 4,115,145 shares of the medical research company’s stock worth $853,028,000 after buying an additional 311,545 shares during the last quarter. Institutional investors own 76.94% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Story: Put Option

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.